DNMT1 and urinary bladder cancer: We also have demonstrated that sensitization of cisplatin resistant bladder cancer cell lines can be achieved in vitro by pre-treatment using the Food and Drug Administration (FDA)-approved DNMT inhibitor decitabine alone and in combination with the HDAC inhibitor vorinostat, confirming a previous in vitro finding on cisplatin and decitabine co-treatment in bladder cancer cells by Shang et al. [25].